title: Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer.
abstract: The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we describe the technological advances in the field of CARs and highlight critical components of its success. Additionally, we describe how various laboratories have worked toward developing new, safer, and more potent CARs for cancer.
authors: University of Pennsylvania, Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Product Development & Correlative Sciences laboratory, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5156, United States.
authors: Jan J
authors: JJ
authors: Melenhorst
authors: Simon F
authors: SF
authors: Lacey
authors: Felipe
authors: F
authors: Bedoya
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D058615:Synthetic Biology; D013601:T-Lymphocytes / Q000378:metabolism / Q000637:transplantation*; D016896:Treatment Outcome
chemical_list: D011948:Receptors, Antigen, T-Cell
keywords: Cell therapy; chimeric antigen receptor (CAR); gene therapy; synthetic biology.